Advances in targeted therapy for metastatic non-squamous NSCLC have now expanded from EGFR and ALK to additional oncogenic targets, including ROS1, BRAF, RET, HER2, NTRK, and MET. Here, ALK is linked to non-small cell lung carcinoma.